Hydra Biosciences, Inc.

Syros Pharmaceuticals, Inc.

Envivo Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.

Forum Pharmaceuticals, Inc.

Other

The Scripps Research Institute

The Rockefeller University

Ember Therapeutics, Inc.

Daimed

Eli Lilly and Company

Amy Ripka

Gideon Shapiro

Richard Chesworth

Jayhong A Chong

Glenn R Larsen

Christopher Fanger

Magdalene M Moran

Manfred Weigele

Dennis John Underwood

Xiaoguang Zhen

Dansu Li

Stephane Ciblat

Kevin Sprott

Jason J Marineau

Darby Schmidt

Anzhelika Kabro

Melissa Leblanc

Stephanie Roy

Dana K Winter

Tom Miller

Serge Leger

M Arshad Siddiqui

William C Lumma

Peter C Meltzer

Michael Bradley

Anu Mahadevan

Howard P Ng

Matthew Gregory Bursavich

Andrew J McRiner

Guoli Zhang

Jeffrey O Saunders

Steven P Adams

Jian Lin

Lei Jin

Kerry Leigh Spear

Theodore M Kamenecka

Thomas D Bannister

Manuel A Navia

Cassandra Celatka

Tsvetelina Ivanova Lazarova

Patrick Griffin

Hongfeng Deng

Mary Jeanne Kreek

Roger Xie

Arshad Siddiqui

Gerhard Koenig

Michael Rynkiewicz

Zihong Guo

Nizal Chandrakumar

Scott T Moe

Eduardo Butelman

Donato Del Camino

Neil Hayward

Pamela Nagafuji

James E Stickler

Brian Reed

Andrew Mcriner

Howard Ng

1-Phenylacetyl-8-aminohexahydro-2H-pyrano[3,4-b]pyrazines of formula are disclosed. The compounds are kappa ligands and are useful to treat drug dependency, pruritus, pain, and inflammation.

Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject. 

Inhibitors of cyclin-dependent kinase 7 (CDK7)

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

Imidazotriazinone compounds

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.

Compounds for modulating TRPV3 function

The invention provides molecular entities that bind with high affinity to PPARG (PPAR&#x3b3;), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

N-biphenylmethylbenzimidazole modulators of PPARG

1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not to, those associated with cognitive deficits or schizophrenic symptoms.

1,2-disubstituted heterocyclic compounds

Compounds of modulating TRPV3 function

Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof.

Phenoxymethyl heterocyclic compounds

1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

Growing community of inventors

Reading, MA, United States of America

Amy Ripka